The US Food and Drug Administration is moving to speed drug development and review by launching real-time clinical trials.

The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.

For children treated for suspected septic shock, outcomes were similar in fluid resuscitation with balanced crystalloid fluid vs 0.9% saline.

Physical activity-based interventions may help reduce chronic postsurgical pain, but current evidence is inconclusive.

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Florida’s KidCare expansion has been mired in lawsuits and ongoing negotiations between the state and federal regulators.

For patients with early infection with Lyme disease, standard and modified 2-tiered testing diagnostic algorithms have low sensitivity.

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive ...

The FDA has accepted for Priority Review the New Drug Application for bepirovirsen for the treatment of adults with chronic hepatitis B.

A new proposal could make it easier for patients to access breakthrough medical devices through Medicare insurance.

Participation in state AIDS Drug Assistance Programs was associated with improved HIV treatment outcomes and high rates of viral suppression.

A new effort to prepare for future avian influenza outbreaks is moving forward despite a major funding setback.